18th ICASA | 29 NOV - 4 DEC 2015 | HARARE | ZIMBABWE
INTERNATIONAL CONFERENCE ON AIDS AND STIs IN AFRICA
ICASA 2015 Zimbabwe > ABSTRACTS > Track Descriptors
Abstracts

Track Descriptors

AIDS in Post 2015: Linking Leadership, Science and Human Rights

 

Track A: Basic Science
Areas and Objectives

This track will encompass all aspects of fundamental HIV biology and the host response to HIV. Areas of focus will include HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, interaction of micronutrients, co-infection and progress in animal models. Pre-clinical vaccine, microbicides, and drug development will be important themes of this track.

HIV evolution, viral diversity and bioinformatics

A1. HIV-1/2: Origins, evolution, diversity and response to ARV
A2. Molecular epidemiology of HIV diversity
A3. Bioinformatic analysis of HIV diversity and drug resistance

Immunology of HIV

A4. Innate immune responses and function in natural history of HIV infection
A5. Humoral immune responses and function in natural history of HIV infection
A6. Cellular immune responses and function in natural history of HIV infection
A7. Immune responses in resistant cohorts: elite controllers and exposed uninfected

Pathogenesis (HIV-1/2)

A8. Viral determinants of HIV pathogenesis
A9. Acute and early HIV infection

Host genetics and HIV infections

A10. Host genetics of resistance and susceptibility and restriction factors

HIV transmission and early infections

A11. Animal models of transmission, disease resistance and progression
A12. HIV transmission (mucosal and mother to child transmission; other transmission)

HIV: Co-infections and emerging pathogens

A13. HIV super-infection
A14. HIV co-infection with TB and other pathogens
A15. HIV interactions with emerging and other opportunistic pathogens

HIV: Drug development and resistance

A16. HIV drug development: Synthetic, traditional and microbicides
A17. Molecular mechanisms of drug action and antiviral drug resistance and drug interaction
A18. Nucleic acid based HIV and SIV therapies

Vaccine development

A19. Clinical trials in HIV vaccine development
A20. Animal models for vaccine development

Interaction of micronutrients and HIV infection

A21. Effect of micronutrients in HIV and AIDS pathogenesis, transmission and treatment
A22. Mechanisms of micronutrient and HIV interactions

Rapid diagnostics tools development (for use in resource limited settings)

A23. Novel assays of immune responses in HIV and AIDS and virological monitoring
A24. Rapid and cost-effective HIV screening and diagnostic methods
A25. HIV drug resistance testing

 


 

Track B: Clinical Science, Treatment and Care
Areas and Objectives

This track will analyze clinical features of opportunistic infections, malignancies, severe bacterial diseases, co-morbidities in people living with HIV. Issues to antiretroviral therapy, response to ART, adherence, retention, long term follow-up, management of side effects, ART in specific populations (adolescents, Elderly, pregnant women) will also be addressed. Emerging topics such as aging, frailty and in other age-related comorbidities such as cardiovascular, renal, neurocognitive, bone mineral and metabolic diseases will be discussed. Issues of resistance and management of failure including salvage therapy which is a concern in resources limited settings will be addressed.

Clinical course of HIV infection and disease

B1. Natural history of HIV Disease including markers of HIV Disease progression
B2. Challenges associated with pre-ART patient care
B3. Morbidity and mortality during ART

Diagnosis and treatment of co-infections/co-morbidities

B4. Co-infections (TB, Hepatitis, STIs, Cryptococcus, bacterial diseases, leishmaniasis, Malaria and others)
B5. Prophylaxis against common infections (CPT, IPT, antifungal), immunization in HIV infected people
B6- Tools for diagnosis and management of infections: point of care
B7. HIV and non-communicable diseases (diabetes, cardiovascular, renal diseases, bone mineral diseases, HIV and neurocognitive disorders)
B8. HIV and malignancies

Antiretroviral therapy

B9. First line therapy (when to start, what to start with, durability)
B10. ART monitoring strategies
B11. Treatment failure: drug resistance, second line therapy and salvage therapy
B12. Adherence and retention
B13. Antiretroviral therapy in children
B14. HIV management in adolescents
B15. Antiretroviral therapy in pregnant women
B16 Antiretroviral therapy in elder populations
B17. Adverse effects of antiretroviral therapy including immune reconstitution syndrome
B18 Long term follow-up
B19. Co-morbidities: TB, HBV, HBC,
B20. HIV-2, HIV-1+2 infections
B21- Management of HIV infection in drugs users (IVDU)
B22. Cost effectiveness of ART
B23. – Antiretroviral therapy to prevent HIV-Transmission

Palliative care and nutrition

B24. Pain management and end of life care
B25. Clinical nutritional care in HIV infection
B26. Home and community based care and support
B27 Other Strategies and Therapies (traditional medicine, spiritual care)

Clinical guidelines, tools and algorithms

B28. Country adaptation of global HIV diagnosis and treatment guidelines
B29. Diagnosis and monitoring tools


 

 

Track C: Epidemiology and Prevention Science
Areas and Objectives

This track will focus on HIV/AIDS prevention research and issues related to the design, implementation and evaluation of prevention programs to reach the MDG and the Post MDG.It will include examination of methodological and programmatic advances in the continuum of prevention research, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. Strategies to put HIV prevention research into practice, efforts to promote preparedness for bio-medical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre- and post-exposure prophylaxis, circumcision and other methods will be presented. This Track will also address co-morbidities (Hepatitis, Tuberculosis, and STI) and emergency diseases like Ebola

Basic HIV Epidemiology

C1. Natural history and Molecular epidemiology of HIV
C2. HIV prevalence and incidence trends
C3. Risk factors for acquisition of HIV, geographic heterogeneity and contextual
C4 Epidemiology in general population
C5 Epidemiology of HIV in adolescents and children
C6 HIV in most at risk populations (sex workers, MSM, prisoners, IDU, migrants)

Epidemiology of HIV co‐morbidity

C7. HIV and other sexually transmitted infections (STI)
C8. HIV and Tuberculosis co‐infection
C9. HIV and Malaria co‐infection
C10. HIV and other opportunistic infections (Viral hepatitis, etc)
C11. HIV and non‐communicable diseases
C12. HIV and associated cancers

Social Epidemiology of HIV

C13. Sexual behavior, vulnerability and Most at Risk Populations (MARPS)
C14. Socio‐cultural and economic determinants of HIV

HIV epidemiology in the era of ART

C15. Relapse of risky behavior with the advent of ART
C16. Modeling HIV epidemic in the advent of ART

HIV/AIDS Surveillance and Monitoring and Evaluation

C17. HIV and AIDS surveillance: Routine, sentinel and second generation
C18. Surveillance of opportunistic infections, ART drug resistance
C19. Population‐based HIV seroepidemiologic studies, and measuring new HIV infections, including in children
C20. Monitoring and evaluation of HIV/AIDS programs

Methodological Issues and Capacity‐Building in Epidemiological and Prevention Research

C21. Novel research designs in HIV and AIDS
C22. Ethical issues in epidemiological and prevention research
C23. Measuring and modeling the impact of the HIV epidemic
C24. Methods aimed at measuring recent HIV infections and HIV incidence
C25. Surveillance systems and methods

HIV/AIDS Prevention Programmes

C26. HIV counseling and testing
C27. Prevention of Mother to Child Transmission
C28. Prevention programmes in institutional and community settings
C29. Prevention programmes for immigrants, mobile and displaced populations
C30.Positive prevention programmes for PLWHIV
C31. HIV Prevention technologies
C32. New approaches for HIV prevention
C33 Integrating HIV prevention into reproductive health, care, support and treatment programmes

 


 

Track D: Social Science, Human Rights and Political Science
Areas and Objectives

This track aims to highlight new knowledge and address gaps in the translation of behavioral and social science evidence into practice, and to contribute to the building of theory and understanding in HIV-related social science. The track also aims to promote understanding of the individual and social determinants of HIV-related risk, vulnerability and impact, to inform development of effective and sustainable HIV responses. This track will feature research, analysis and evaluation on psychosocial factors that shape individual attitudes, experiences, and behaviors; social and structural factors that shape vulnerability and risk; social and cultural norms that underlie individual risk and community vulnerability; programmes that promote access to HIV and STI prevention, treatment, care and support; social and structural factors that shape vulnerability; and methods and outcomes of individual and community engagement, leadership, empowerment, and self-determination.

Individual determinants of HIV-related risk and vulnerability

D1 Unsafe sexual practices
D2 Risk taking, drug and alcohol consumption
D3 Mental health
D4 Discordant couples – managing risk, managing desire

Behavioural interventions: How do we influence individual behaviour through one-to-one and group interventions?

D5 Emerging approaches to HIV prevention
D6 The role of HCT, and behaviour change counselling, in behaviour change
D7 Community mobilisation for HIV prevention, treatment, care and support

Communication, media and education: How do we educate and inform people?

D8 HIV and AIDS communication strategies
D9 The media and HIV and AIDS
D10 HIV and HIV prevention in the education sector
D11 Digital media, social networking and HIV prevention, treatment, care and support

Socio-cultural factors and HIV: How does the social context influence behaviour?

D12 Family structures, kinship and social safety nets for vulnerable groups (orphans, widows, others)
D13 Harmful traditional practices and HIV
D14 Young people and sexuality
D15 Sex work and other forms of transactional sex

Structural factors and HIV: How do systems and structures influence behaviour?

D16 Poverty, social and socio-economic structures and HIV
D17 Addressing a feminized epidemic in sub Saharan Africa
D18 Fertility, family planning and reproductive health services and HIV
D19 Reproductive rights, health and HIV
D20 Family-centred approach to HIV care and support

Living with HIV: How can PLHIV live meaningful, fulfilling and longer lives?

D21 Adherence and retention in HIV treatment and care
D22 Living with co-infections (TB, HBV, HCV, HPV, etc)
D23 Growing up with HIV and adaptation/ teenage sexuality
D24 Stigma and discrimination

The role of theory: How do we theorise our work as social scientists and researchers?

D25 HIV prevention theories and approaches
D26 Social and behavioural science collaboration in biomedical research and services
D27 Methods in social and behaviour surveys

Human rights, law and ethics

D28  Making the law work for the HIV response Protection, empowerment and involvement of PLWHIV and vulnerable populations
D29  Human rights and HIV services for vulnerable populations (prisoners, people who use drugs, sexual minorities and sex workers)
D30 Stigma and discrimination and access to justice in national AIDS responses
D31 Human rights, ethics and the strategic use of antiretroviral drugs (ARVs) for treatment and prevention
D32  Human rights and HIV testing: bridging the gaps in policy and practice
D33    Human rights, culture and religion in the HIV epidemic

Drug and substance abuse

D34 Drugs and alcohol use, social and psycho-social issues
D35 Social, behavior and cultural issues in harm reduction approaches

 


 

Track E: Health Systems, Economics and Implementation Science
Areas and Objectives

This track will aim to provide new insights into the status of the health systems and its capacity and challenges to expanding treatment and prevention in resource-limited settings. At the same time, issues related to health economics, integration of health programs, country ownership of national health and HIV programs, and advancement of a comprehensive and integrated approach to health and rights will be discussed. This Track must show the need for a holistic vision of the fight against the disease by the effective strengthening of health systems. The verticalization of the fight is not a proper and appropriate response in a context where we have recurrent epidemics This Track must show the need for a holistic vision of the fight against the disease by the effective strengthening of health systems. The verticalization of the fight is not a proper and appropriate response in a context where we have recurrent epidemics

 

HIV and health system strengthening

E1.      Leveraging the AIDS response to strengthen health systems and improve other health outcomes
E2.      Developing Africa’s response to the crisis in human resources for health
E3.      Procourment and supply management for health care delivery
E4.      Health infrastructure and laboratory services
E5.     Positioning HIV and Health within the Post-2015 MDG Agenda

Shared responsibility and global solidarity towards sustainable AIDS and health agenda

E6.      Governance – peer review and accountability mechanisms
E7     Effective national leadership – indicators and benchmarks to measure progress to greater country ownership
E8.      Investing in HIV more strategically – use of applications of investment approach at country level
E9.      New Funding Model of the Global Fund
E10   Ensuring accelerated access to affordable and quality-assured medicines and health-related commodities – Pharmaceutical Manufacturing Plan in Africa (PMPA)

Health economics

E11 Strategies to integrate HIV interventions with other health programs
E12.      Integrating HIV services with other development programs (poverty, education, water and hygiene, nutrition)
E13.      Impact evaluation of different models of health service delivery (cost effectiveness)

Partnership in HIV

E14.      Private-public, faith-based organizations and NGOs partnerships for prevention, treatment, care and support (service delivery, financing)
E15.      Securing resources and capacity for effective partnership
E16.      Civil society: A driving force in Getting to Zero – Operationalizing partnership with civil society, people living with HIV and key populations

Monitoring and evaluation

E17.      HIV/AIDS data management information for monitoring and evaluation and evidence-informed decision making
E18.      Status and capacity of national health information systems

Innovation and best practices

E19 Task shifting, sharing and delegation in national programs and responses
E20.      Standardization in the delivery of health service packages
E21.      Security, international relations and humanitarian disasters

Key populations and HIV

E22.      Disabled, Incarcerated, Elderly, Street Children
E23.      MSMs, sex workers and IDUs
E24.      Women, girls, HIV and gender inequality
E25.      Human trafficking, sexual violence and HIV
E26.      Orphans and vulnerable children and HIV
E27.      Application of information technology for HIV prevention, care and treatment and for community mobilization

 

ONGOING
ACCOMMODATION
SECURE YOUR VISA
OFFICIAL CARRIER OF ICASA 2015